Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02002871
Other study ID # EczemaCT01
Secondary ID CIV-13-08-011581
Status Completed
Phase N/A
First received December 2, 2013
Last updated June 24, 2015
Start date October 2013
Est. completion date March 2014

Study information

Verified date June 2015
Source Light and Health Venture
Contact n/a
Is FDA regulated No
Health authority Germany: Ethics CommissionGermany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of treatment with 453nm blue light with no treatment in patients with Eczema. Patients will be screened up to 28 days before start of treatment. During the screening visit, the purpose and procedures of the study will be explained to potential patients and informed consent will be obtained. In addition, fungal superinfection of the target area will be examined using direct preparations and mycology cultures. At the baseline visit, patients with Eczema will be determined and all inclusion and exclusion criteria will be assessed. For eligible patients, two comparable treatment areas will be randomized to treatment with blue light (target area) or to serve as untreated control area. After randomization, patients will receive treatment of the target area with 3 applications per week at the investigational site for a total treatment period of 4 weeks. During those 4 weeks, safety and effectiveness assessments will be performed at weekly intervals. After end of treatment, the patients will be followed-up for another 2 weeks. In case no full resolution of adverse events occurred at the 2 week follow-up visit, a follow-up call will be performed after another 2 weeks. Treatment responses will be photo documented


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Signed and dated informed consent prior to any study-mandated procedure

2. Good health as determined by the Investigator according to physical examination

3. Willing and able to comply with study requirements

4. Skin type I-IV according to Fitzpatrick

5. Eczema, severity defined by an Eczema Area Severity Index (EASI)smaller/equal 20

6. Comparable clinical symptomatology of both intended treatment Areas

8. Reliable method of contraception for women of childbearing potential (i.e. low failure rate less than 1% per year; e.g. oral contraceptives, intrauterine device [IUD] or transdermal contraceptive patch) 9. Willing to abstain from excessive sun / UV exposure (e.g. sunbathe, solarium) during the course of the study

Exclusion Criteria:

1. Inmates of psychiatric wards, prisons, or other state institutions

2. Investigator or any other team member involved in the conduct of the clinical study

3. Participation in another clinical trial within the last 30 days

4. Pregnant and lactating women

5. Photodermatosis and/or Photosensitivity

6. Porphyria and/or hypersensitivity to porphyrins

7. Congenital or acquired immunodeficiency

8. Patients with any of the following conditions present on the study areas; Malignoma of the skin or severe actinic damage of the skin, atypical naevi or signs of hyperpigmentation, precancerosis viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections and atrophic skin

9. Patients with genetic deficiencies attached with increased sensitivity to light or increased risk to dermatologic cancer (i.e. Xeroderma pigmentosum, Cockayne Syndrome, Bloom- Syndrome)

10. Current diagnosis of exfoliative or toxic dermatitis.

11. Evidence of superinfection of the intended treatment areas

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
PSO-CT02 device
The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.

Locations

Country Name City State
Germany Klinik for Dermatology and Allergology, medical faculty of the RWTH Aachen Aachen NRW

Sponsors (1)

Lead Sponsor Collaborator
Light and Health Venture

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Hyperpigmentation - Evaluation by Mexameter Higher values describe a higher level of pigmentation. week 0, 2, 4, 6 Yes
Other Adverse Events (Serious and Non-serious) week 0, 2, 4, 6 Yes
Other Adverse Device Events (Serious and Non-serious) over 6 weeks Yes
Other Device Deficiencies This measure describes device deficiencies in general leading to a non functional device. No specific characteristics were assessed. over 6 weeks Yes
Other Recovery of Hyperpigmentation During Follow up Period (Compared to Last Treatment) Higher values describe a higher level of pigmentation. week 6 Yes
Other Number of Participants With Acceptance of Hyperpigmentation at Week 6 Questionaire if hyperpigmentation was acceptable if reported. Outcome was number of patients answering "yes" or "no". week 6 Yes
Primary Change From Baseline (Visit 2) of the Sum Score of Local Eczema Rating of the Target Area as Compared to the Control Area at End of Treatment The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)). at week 4 No
Secondary Change From Week 4 of the Sum Score of Local Eczema Rating as Compared to the Control Area at End of Follow-up The investigator rated the key symptoms erythema, induration/papulation/edema, excoriation, lichenification and crusts on a score of 0-3 (none, mild, moderate, and severe) with half steps allowed. A total severity score was calculated as the sum of the single symptom ratings (range 0-15 whereas 0 (best) - 15 (worst)). week 6 No
Secondary Change From Baseline of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area Higher values describe higher erythema levels. week 4, 6 Yes
Secondary Change From Week 4 (End of Treatment) of Inflammation (Erythema) Evaluated by Mexameter of the Target Area as Compared to the Control Area at End of Follow-up Higher values describe a higher level of erythema. week 6 Yes
Secondary Change From Baseline of Patient Rating of Itching of the Target Area as Compared to the Control Area patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching) week 4, 6 No
Secondary Change From Week 4 (End of Treatment) of Patient Rating of Itching of the Target Area as Compared to the Control Area at End of Follow-up patients were asked to rate itching on a VAS scale (1 no itching; 100 worst imaginable itching). week 6 No
See also
  Status Clinical Trial Phase
Completed NCT01257061 - Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment Phase 3
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Recruiting NCT05439577 - A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02075632 - Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream Phase 2
Completed NCT00143819 - Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis Phase 2
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT04358224 - The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment Phase 4
Not yet recruiting NCT04520308 - An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis Phase 4
Recruiting NCT03340155 - Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases N/A
Completed NCT04023084 - Response of Children With Atopic Dermatitis (Eczema) to Eucrisa Phase 4
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Completed NCT05583019 - Atopic Dermatitis With Accelerometry and Polysomnography (ADAP)
Completed NCT03293030 - Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis Phase 4
Completed NCT01420705 - Bacille Calmette-Guérin (BCG) Vaccine and Atopy N/A
Recruiting NCT01012453 - A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema N/A
Completed NCT00375713 - Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Phase 3
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research